Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. [electronic resource]
Producer: 20101108Description: 731-41 p. digitalISSN:- 1876-7605
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- genetics
- Aged
- Angioplasty, Balloon, Coronary -- adverse effects
- Aryl Hydrocarbon Hydroxylases -- genetics
- Chi-Square Distribution
- Clopidogrel
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP3A -- genetics
- Drug Resistance -- genetics
- Female
- Gene Frequency
- Genotype
- Humans
- Logistic Models
- Male
- Middle Aged
- Odds Ratio
- Phenotype
- Platelet Activation -- drug effects
- Platelet Aggregation Inhibitors -- administration & dosage
- Platelet Function Tests
- Polymorphism, Genetic
- Registries
- Republic of Korea
- Risk Assessment
- Risk Factors
- Ticlopidine -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.